Abstract
Objective: The current study was designed to evaluate the ability of an epitope independent microfluidic cell capture device to isolate circulating tumor cells (CTCs) from the blood of women with stage III–IV high-grade serous ovarian cancer (HGSOC) that could subsequently be evaluated using either a highly multiplexed gene expression assay or by immunofluorescence (IF).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
